Trial · NCT00777036
Outcomes21
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 20 of 21
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Major Cytogenetic Response (MCyR) Rate | From first dose of study therapy until 30 days after last dose (Assessed up to September 2016, approximately 90 months) | Primary efficacy endpoint pre-specified only for participants treated in Cohort 1 | percentage of participants | NUMBER |
| PRIMARY | Complete Hematologic Response (CHR) Rate | From first dose of study therapy until 30 days after last dose (Assessed up to September 2016, approximately 90 months) | Primary efficacy endpoint pre-specified only for participants treated in Cohort 2 | percentage of participants | NUMBER |
| PRIMARY | Complete Cytogenetic Response (CCyR) Rate | From first dose of study therapy until 30 days after last dose (Assessed up to September 2016, approximately 90 months) | Primary efficacy endpoint pre-specified only for participants treated in Cohort 3 | percentage of participants | NUMBER |
| SECONDARY | Major Cytogenetic Response (MCyR) Rate in Cohort 2 | From first dose of study therapy until 30 days after last dose (Assessed up to September 2016, approximately 90 months) | Secondary efficacy endpoint pre-specified only for participants treated in Cohort 2 | percentage of participants | NUMBER |
| SECONDARY | Complete Hematologic Response (CHR) Rate in Cohorts 1 and 3 | From first dose of study therapy until 30 days after last dose (Assessed up to September 2016, approximately 90 months) | Secondary efficacy endpoint pre-specified only for participants treated in Cohort 1 and Cohort 3 | percentage of participants | NUMBER |
| SECONDARY | Rate of Best Cytogenetic Response | From first dose of study therapy until 30 days after last dose (Assessed up to September 2016, approximately 90 months) | All treated participants | percentage of participants | NUMBER |
| SECONDARY | Time to Major Cytogenetic Response (MCyR) | From first dose until MCyR criteria are met (assessed up to September 2016, approximately 90 months) | All treated participants with MCyR | months | MEDIAN |
| SECONDARY | Duration of Major Cytogenetic Response (MCyR) | From first day criteria are met for MCyR until the date PD is reported or death (assessed up to September 2016, approximately 90 months) | All treated participants with MCyR | months | MEDIAN |
| SECONDARY | Time to Complete Cytogenetic Response (CCyR) | From first dose until CCyR criteria are met, assessed up to September 2016 (approximately 90 months) | All treated participants with CCyR | months | MEDIAN |
| SECONDARY | Duration of Complete Cytogenetic Response (CCyR) | From first day criteria are met for CCyR until the date of progressive disease or death (assessed up to September 2016, approximately 90 months) | All treated participants who achieved CCyR | months | MEDIAN |
| SECONDARY | Progression-Free Survival (PFS) | 174 Months | All treated participants | Months | MEDIAN |
| SECONDARY | Time to Complete Hematologic Response (CHR) | From first dose until CHR criteria are met, assessed up to September 2016 (approximately 90 months) | All treated participants with CHR | months | MEDIAN |
| SECONDARY | Duration of Complete Hemotologic Response (CHR) | From first day criteria are met for CHR until date of disease progression or death (assessed up to September 2016, approximately 90 months) | All treated participants with CCyR | months | MEDIAN |
| SECONDARY | Disease-Free Survival | 168 Months | All treated participants with response of CCyR or CHR | Months | MEDIAN |
| SECONDARY | Overall Survival (OS) | 174 Months | All treated participants | Months | MEDIAN |
| SECONDARY | Major Molecular Response (MMR) Rate | From date of first treatment to date of MMR (assessed up to Jan 2025, approximately 15 years and 10 months) | All treated participants | percentage of participants | NUMBER |
| SECONDARY | Complete Molecular Response (CMR) Rate | From date of first treatment to date of CMR (assessed up to Jan 2025, approximately 15 years and 10 months) | All treated participants | percentage of participants | NUMBER |
| SECONDARY | Major Cytogenetic Response (MCyR) Rate up to 2 Years | 24 months | All treated participants | percentage of participants | NUMBER |
| SECONDARY | Complete Cytogenetic Response (CCyR) Rate up to 2 Years | 24 months | All treated participants | percentage of participants | NUMBER |
| SECONDARY | Major Molecular Response (MMR) Rate up to 7.5 Years | 90 months | All treated participants | percentage of participants | NUMBER |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00777036/outcomes